Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
- 15 February 2024 - 1 mins read
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
Related Press Releases
![Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
26 July 2024
12 mins read
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
![Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
25 July 2024
7 mins read
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
![Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
25 July 2024
11 mins read
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
![Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
![Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
10 June 2024
12 mins read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
![Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
07 June 2024
6 mins read
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
![Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
06 June 2024
5 mins read
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
![Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
05 June 2024
7 mins read
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
![Ipsen appoints Keira Driansky as EVP, President of North America Ipsen appoints Keira Driansky as EVP, President of North America](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
02 May 2024
5 mins read